Kwality Pharmaceuticals Share Price

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Kwality Pharmaceuticals announced Q1FY27 results</strong></span></h3> <p _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Consolidated Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c2478508423="">Total Revenue: For Q1FY27, the consolidated total revenue stood at Rs 16,297.49 lakh, representing an increase of 45.70% compared to Rs 11,185.47 lakh in Q1FY26 (YoY) and a growth of 3.04% from Rs 15,817.17 lakh in Q4FY26 (QoQ).</li> <li _ngcontent-ng-c2478508423="">Revenue from Operations: Net revenue from operations in Q1FY27 was Rs 16,235.22 lakh, up by 45.63% from Rs 11,147.90 lakh in Q1FY26 (YoY) and up by 3.33% from Rs 15,711.36 lakh in Q4FY26 (QoQ).</li> <li _ngcontent-ng-c2478508423="">Net Profit: The company reported a consolidated net profit for the period of Rs 2,562.23 lakh in Q1FY27, marking a significant growth of 114.96% compared to Rs 1,191.97 lakh in Q1FY26 (YoY) and an increase of 1.23% from Rs 2,531.05 lakh in Q4FY26 (QoQ).</li> <li _ngcontent-ng-c2478508423="">Earnings Per Share (EPS): Basic and diluted EPS for Q1FY27 stood at Rs 24.69, compared to Rs 11.49 in Q1FY26 and Rs 24.39 in Q4FY26.</li> <li _ngcontent-ng-c2478508423="">Total Comprehensive Income: The total comprehensive income for the period was Rs 2,571.23 lakh in Q1FY27, reflecting robust growth compared to Rs 1,207.08 lakh in Q1FY26.</li> </ul> <p _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Standalone Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c2478508423="">Total Revenue: Standalone total revenue for Q1FY27 was Rs 16,297.49 lakh, showing an increase of 45.70% from Rs 11,185.47 lakh in Q1FY26 (YoY) and a rise of 3.23% from Rs 15,788.04 lakh in Q4FY26 (QoQ).</li> <li _ngcontent-ng-c2478508423="">Revenue from Operations: Standalone net revenue from operations stood at Rs 16,235.22 lakh in Q1FY27, compared to Rs 11,147.90 lakh in Q1FY26 and Rs 15,682.24 lakh in Q4FY26.</li> <li _ngcontent-ng-c2478508423="">Net Profit: The standalone net profit reached Rs 2,562.68 lakh in Q1FY27, a growth of 114.77% against Rs 1,193.22 lakh in Q1FY26 (YoY) and a growth of 1.33% from Rs 2,529.11 lakh in Q4FY26 (QoQ).</li> <li _ngcontent-ng-c2478508423="">Earnings Per Share (EPS): Standalone basic and diluted EPS was Rs 24.70 for Q1FY27, compared to Rs 11.50 in Q1FY26 and Rs 24.37 in Q4FY26.</li> </ul> <p _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Business Highlights:</strong></p> <ul> <li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Guidance Update:</strong> Building on the momentum of a strong FY26, the management has raised FY27 guidance across key metrics: <ul> <li _ngcontent-ng-c2478508423="">Revenue: Rs 700+ crore (+39%+ YoY).</li> <li _ngcontent-ng-c2478508423="">EBITDA: Rs 189-196+ crore (27-28%+ margin).</li> <li _ngcontent-ng-c2478508423="">PAT: Rs 109+ crore (~15.5%+ margin).</li> </ul> </li> <li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">R&D and Clinical Programme:</strong> During the quarter, the company completed 13 Bioequivalence (BE) studies (7 from the General unit, 2 from Beta Lactam, and 4 from Oncology) as part of its 40-molecule BE programme. Filings have been made in <strong _ngcontent-ng-c2478508423="">15+ countries</strong>.</li> <li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Product Registrations:</strong> The company secured 15+ new key product registrations across Malaysia, Algeria, Peru, and Mexico during the quarter.</li> <li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Biologics Front:</strong> Received approval to initiate pre-clinical batches for Pembrolizumab, adding a second biologics candidate. Erythropoietin has progressed to the clinical trial stage.</li> <li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Facility Update:</strong> Construction of the Hormone manufacturing facility is on schedule, with completion anticipated by November 2026.</li> <li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Global Presence:</strong> The company operates five manufacturing facilities and has a presence in over 70+ countries.</li> </ul> <p><a class="lb" href="/get-document/post/pdf/5776428/" target="_blank">Result PDF</a></p>

• Trendlyne
• 1 day 12 hours ago

Investor Presentation for quarter ended June 30, 2026.

• BSE India
• 1 day 12 hours ago

Financial Results for Quarter Ended June 30, 2026.

• BSE India
• 1 day 12 hours ago